Lidocard (Lidocaine Hydrochloride Monohydrate)

Lidocaine blocks voltage‑gated sodium channels on neuronal and cardiac cell membranes, preventing sodium influx during depolarisation. This stabilises the membrane, stops nerve impulse propagation, and reduces abnormal cardiac automaticity, resulting in loss of sensation and anti‑arrhythmic effects.

The specific dose of Lidocard is determined by the prescribing clinician based on the patient’s condition, weight, age, and clinical response. Healthcare professionals calculate the appropriate amount and rate of intravenous administration for each individual case.

Safety data for Lidocard in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Lidocard, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Lidocard (lidocaine) is an amide‑type local anaesthetic with a rapid onset and moderate duration, often preferred over bupivacaine for procedures requiring quick recovery. For ventricular arrhythmias, lidocaine is shorter‑acting than class I agents such as procainamide, allowing tighter control during acute events.

Lidocard should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discoloured or contains particles.

Lidocard is administered intravenously by a qualified healthcare professional. It is typically given as a slow injection or infusion, with the rate adjusted to achieve the desired anaesthetic depth or anti‑arrhythmic effect while monitoring the patient’s cardiac and neurological status.

The most serious risks include seizures, severe allergic reactions (anaphylaxis), and cardiac arrest or profound arrhythmias. Immediate medical intervention is required if any of these events occur, and continuous monitoring is essential during intravenous administration.

Lidocard should not be used in individuals with a known hypersensitivity to lidocaine or other amide‑type local anaesthetics, in patients with severe heart block without a pacemaker, or in those with significant hepatic impairment where dose reduction is not feasible.